Phase 1
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
The asset, LYT-100, is an oral compound that has shown anti-fibrotic and anti-inflammatory properties.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
In late June, Minovia Therapeutics dosed the first patient in a Phase I/II clinical trial with Pearson syndrome. The company is one of the first to make headway in treating rare mitochondrial diseases.
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
The beginning of virtual clinical trials is going to be a game-changer. Why they are going to be game-changer? What changes will occur? Know it all here.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome
PRESS RELEASES